$1.21
-5.31%
2026-09-04 12:19:29 EDT-$0.07
보건 의료
생명공학
NASDAQ
활발히 거래 중
Cadrenal Therapeutics, Inc.는 주로 임상 개발에 종사하는 바이오제약 기업으로 운영되고 있습니다. 회사의 핵심은 희귀의약품 지정(오펀 드러그 디자인레이션)을 받은 새로운 치료제인 Tecarfarin의 발전에 ...
Cadrenal Therapeutics, Inc.는 주로 임상 개발에 종사하는 바이오제약 기업으로 운영되고 있습니다. 회사의 핵심은 희귀의약품 지정(오펀 드러그 디자인레이션)을 받은 새로운 치료제인 Tecarfarin의 발전에 ...
CAD-1005 is a phase 3-ready, investigational small molecule therapy that selectively inhibits 12-LOX. Unlike standard HIT therapies that only prevent thrombotic complications, CAD-1005 is designed to address the primary immune-mediated mechanism driving the disorder. It has received Orphan Drug and Fast Track designations from the FDA.
가격대: N/A (Clinical-stage asset)
페인 포인트: High mortality and morbidity associated with HIT and the limitations of current treatments that only manage symptoms rather than the underlying immune cause.
솔루션: Provides a targeted approach to inhibit the primary immune pathways responsible for HIT, aiming for a reduction in thrombotic events.
대상 사용자: Healthcare providers, critical care hospitals, and patients diagnosed with heparin-induced thrombocytopenia.
Tecarfarin is a novel oral anticoagulant with a mechanism of action similar to warfarin but with a distinct metabolic pathway. It is designed to provide more reliable anticoagulation within a narrow therapeutic window, reducing both thrombotic and bleeding risks in high-risk patients.
가격대: N/A (Clinical-stage asset)
페인 포인트: Difficulty in maintaining consistent anticoagulation in patients with end-stage kidney disease (ESKD) and left ventricular assist devices (LVADs) using standard warfarin or DOACs.
솔루션: Offers a more stable, reliable anticoagulation profile that is easier to manage, reducing the risk of bleeding and thrombotic complications in high-risk cardiovascular patients.
대상 사용자: Patients with end-stage kidney disease (ESKD) with atrial fibrillation and patients with implanted LVADs.
Frunexian is a clinical-stage, intravenous (IV) small molecule inhibitor of Factor XIa. It is specifically engineered for acute, critical care environments, particularly for use during complex cardiac surgeries where medical devices trigger contact activation of coagulation.
가격대: N/A (Clinical-stage asset)
페인 포인트: Coagulation challenges during complex cardiac surgeries and critical care procedures caused by contact activation of blood by artificial surfaces or medical devices.
솔루션: Provides targeted inhibition of the Factor XIa pathway to manage coagulation in acute surgical settings.
대상 사용자: Critical care surgeons, hospitals, and medical centers performing complex cardiac surgeries.